Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
130.00    -0.40 (-0.31%)
Bid:
129.60
Ask:
129.80
Spread: 0.20 (0.154%)
Market Cap: £316.44m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:35 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSFinal Results
1st Apr 20204:41 pmRNSSecond Price Monitoring Extn
1st Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20204:42 pmRNSSecond Price Monitoring Extn
27th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:16 amRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
10th Mar 202010:00 amRNSGelesis: World’s Most Innovative Companies List
10th Mar 20207:00 amRNSNotice of Results
9th Mar 20204:41 pmRNSSecond Price Monitoring Extn
9th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Mar 202012:02 pmRNSPrice Monitoring Extension
5th Mar 20204:40 pmRNSSecond Price Monitoring Extn
5th Mar 20204:35 pmRNSPrice Monitoring Extension
3rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20204:36 pmRNSPrice Monitoring Extension
3rd Mar 202012:02 pmRNSPrice Monitoring Extension
3rd Mar 20207:00 amRNSClinical Trial Initiated Of Wholly-Owned Candidate
2nd Mar 20207:00 amRNSTotal Voting Rights
27th Feb 20204:41 pmRNSSecond Price Monitoring Extn
27th Feb 20204:36 pmRNSPrice Monitoring Extension
25th Feb 20207:00 amRNSAkili ADHD Study in The Lancet Digital Health
18th Feb 20207:00 amRNSPRTC to Present at Leerink Healthcare Conference
3rd Feb 20204:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20204:35 pmRNSPrice Monitoring Extension
3rd Feb 20207:00 amRNSTotal Voting Rights
23rd Jan 20207:00 amRNSPureTech Receives $200M from KRTX Shares
15th Jan 20201:04 pmRNSAkili's New ADHD Trial Met Primary Endpoint
13th Jan 202012:07 pmRNSSecond Price Monitoring Extn
13th Jan 202012:02 pmRNSPrice Monitoring Extension
2nd Jan 20207:00 amRNSTotal Voting Rights
19th Dec 20197:00 amRNSFollica Positive Androgenetic Alopecia Study
17th Dec 201912:00 pmRNSGelesis Partners with US Telehealth Provider
12th Dec 20191:04 pmRNSAkili Meets Primary Endpoint in MDD Clinical Trial
10th Dec 201912:02 pmRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSVedanta & BMS Begin Immuno-Oncology Clinical Study
9th Dec 20197:00 amRNSGelesis Attracts $84M in New Capital for Launch
5th Dec 20197:00 amRNSVedanta MultiDrug Resistance Program Granted $5.8M
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 201912:02 pmRNSPrice Monitoring Extension
21st Nov 20197:00 amRNSKaruna Prices $250M Follow-On Offering
18th Nov 201911:03 amRNSKaruna Successful Ph2 Schizophrenia Study Readout
15th Nov 201912:51 pmRNSresTORbio Update on Phase 3 Trial
13th Nov 20197:00 amRNSPureTech to Present at Jefferies London Conference
5th Nov 20191:00 pmRNSPRTC Presents Novel Oncology Program Data at SITC
5th Nov 201911:00 amRNSGelesis Shares New Plenity Safety & Efficacy Data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.